ReWalk Robotics Ltd. (NASDAQ:LFWD – Get Free Report) Director Michael Swinford bought 21,622 shares of the stock in a transaction dated Monday, November 25th. The stock was acquired at an average price of $2.03 per share, with a total value of $43,892.66. Following the completion of the purchase, the director now owns 65,040 shares of the company’s stock, valued at $132,031.20. This represents a 49.80 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Michael Swinford also recently made the following trade(s):
- On Friday, November 22nd, Michael Swinford acquired 16,907 shares of ReWalk Robotics stock. The shares were bought at an average cost of $1.83 per share, for a total transaction of $30,939.81.
- On Wednesday, November 20th, Michael Swinford acquired 16,471 shares of ReWalk Robotics stock. The stock was bought at an average price of $1.84 per share, with a total value of $30,306.64.
ReWalk Robotics Stock Performance
NASDAQ LFWD opened at $2.10 on Thursday. The stock has a market capitalization of $18.50 million, a P/E ratio of -0.84 and a beta of 2.07. ReWalk Robotics Ltd. has a 52 week low of $1.70 and a 52 week high of $9.10. The stock has a fifty day moving average of $2.54 and a 200-day moving average of $3.49.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reissued a “buy” rating and set a $13.00 price target on shares of ReWalk Robotics in a research note on Wednesday, November 13th.
View Our Latest Research Report on LFWD
Institutional Investors Weigh In On ReWalk Robotics
A hedge fund recently bought a new stake in ReWalk Robotics stock. Dimensional Fund Advisors LP bought a new position in shares of ReWalk Robotics Ltd. (NASDAQ:LFWD – Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 13,548 shares of the company’s stock, valued at approximately $54,000. Dimensional Fund Advisors LP owned 0.16% of ReWalk Robotics as of its most recent filing with the Securities and Exchange Commission. 26.76% of the stock is currently owned by institutional investors.
ReWalk Robotics Company Profile
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.
Recommended Stories
- Five stocks we like better than ReWalk Robotics
- How Technical Indicators Can Help You Find Oversold StocksĀ
- Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
- What Are the U.K. Market Holidays? How to Invest and Trade
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
Receive News & Ratings for ReWalk Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReWalk Robotics and related companies with MarketBeat.com's FREE daily email newsletter.